Advances in systemic therapies for metastatic castration-resistant prostate cancer

The landscape of treatment for metastatic castration-resistant prostate cancer has rapidly evolved during the last 5 years alone. In this review, standard therapies as well as recent advances in the systemic treatment for prostate cancer are explored. Pivotal trial data are summarized with emphasis...

Full description

Saved in:

Bibliographic Details
Published in:	Future oncology (London, England) Vol. 10; no. 14; p. 2213
Main Authors:	Pant, Manish K, Abughaban, Ahmed, Aragon-Ching, Jeanny B
Format:	Journal Article
Language:	English
Published:	England 01-11-2014
Subjects:	Humans Male Neoplasm Metastasis Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - therapy androgen deprivation therapy radium zoledronic acid immunotherapy metastatic castration-resistant prostate cancer abiraterone acetate chemotherapy enzalutamide
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The landscape of treatment for metastatic castration-resistant prostate cancer has rapidly evolved during the last 5 years alone. In this review, standard therapies as well as recent advances in the systemic treatment for prostate cancer are explored. Pivotal trial data are summarized with emphasis on indications for various anti-androgen drugs, androgen-biosynthesis inhibitors, chemotherapy, immunotherapy and bone-targeted agents. The clinical, biochemical and radiographic outcomes for men with metastatic castration-resistant prostate cancer are improving with the establishment of several promising novel agents.
ISSN:	1744-8301
DOI:	10.2217/fon.14.128